These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 18519091)

  • 1. Vasopressin antagonists in polycystic kidney disease.
    Torres VE
    Semin Nephrol; 2008 May; 28(3):306-17. PubMed ID: 18519091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of vasopressin antagonists.
    Torres VE
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E; Rodas L; Blasco M; Molina A; Quintana L
    Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic Kidney Disease and the Vasopressin Pathway.
    van Gastel MDA; Torres VE
    Ann Nutr Metab; 2017; 70 Suppl 1():43-50. PubMed ID: 28614813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hydration in rats and mice with polycystic kidney disease.
    Hopp K; Wang X; Ye H; Irazabal MV; Harris PC; Torres VE
    Am J Physiol Renal Physiol; 2015 Feb; 308(3):F261-6. PubMed ID: 25503729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopressin directly regulates cyst growth in polycystic kidney disease.
    Wang X; Wu Y; Ward CJ; Harris PC; Torres VE
    J Am Soc Nephrol; 2008 Jan; 19(1):102-8. PubMed ID: 18032793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K; Fox A; Gilbert R
    Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.
    Wang X; Constans MM; Chebib FT; Torres VE; Pellegrini L
    Am J Nephrol; 2019; 49(6):487-493. PubMed ID: 31117065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Apr; 13(4):431-4. PubMed ID: 15102592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.
    Aihara M; Fujiki H; Mizuguchi H; Hattori K; Ohmoto K; Ishikawa M; Nagano K; Yamamura Y
    J Pharmacol Exp Ther; 2014 May; 349(2):258-67. PubMed ID: 24570071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
    Devuyst O; Torres VE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):459-70. PubMed ID: 23736843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
    Wang X; Harris PC; Somlo S; Batlle D; Torres VE
    Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
    Zhou JX; Torres VE
    Adv Kidney Dis Health; 2023 May; 30(3):245-260. PubMed ID: 37088527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin receptor antagonists, heart failure, and polycystic kidney disease.
    Torres VE
    Annu Rev Med; 2015; 66():195-210. PubMed ID: 25493947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.
    Beaudoin JJ; Bezençon J; Cao Y; Mizuno K; Roth SE; Brock WJ; Brouwer KLR
    Drug Metab Dispos; 2019 Feb; 47(2):155-163. PubMed ID: 30504136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies to slow polycystic kidney disease.
    Torres VE
    Nephron Exp Nephrol; 2004; 98(1):e1-7. PubMed ID: 15361692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.